Literature DB >> 17251933

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.

Wen Xue1, Lars Zender, Cornelius Miething, Ross A Dickins, Eva Hernando, Valery Krizhanovsky, Carlos Cordon-Cardo, Scott W Lowe.   

Abstract

Although cancer arises from a combination of mutations in oncogenes and tumour suppressor genes, the extent to which tumour suppressor gene loss is required for maintaining established tumours is poorly understood. p53 is an important tumour suppressor that acts to restrict proliferation in response to DNA damage or deregulation of mitogenic oncogenes, by leading to the induction of various cell cycle checkpoints, apoptosis or cellular senescence. Consequently, p53 mutations increase cell proliferation and survival, and in some settings promote genomic instability and resistance to certain chemotherapies. To determine the consequences of reactivating the p53 pathway in tumours, we used RNA interference (RNAi) to conditionally regulate endogenous p53 expression in a mosaic mouse model of liver carcinoma. We show that even brief reactivation of endogenous p53 in p53-deficient tumours can produce complete tumour regressions. The primary response to p53 was not apoptosis, but instead involved the induction of a cellular senescence program that was associated with differentiation and the upregulation of inflammatory cytokines. This program, although producing only cell cycle arrest in vitro, also triggered an innate immune response that targeted the tumour cells in vivo, thereby contributing to tumour clearance. Our study indicates that p53 loss can be required for the maintenance of aggressive carcinomas, and illustrates how the cellular senescence program can act together with the innate immune system to potently limit tumour growth.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17251933      PMCID: PMC4601097          DOI: 10.1038/nature05529

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  30 in total

Review 1.  The p53 pathway: positive and negative feedback loops.

Authors:  Sandra L Harris; Arnold J Levine
Journal:  Oncogene       Date:  2005-04-18       Impact factor: 9.867

2.  Restoration of p53 function leads to tumour regression in vivo.

Authors:  Andrea Ventura; David G Kirsch; Margaret E McLaughlin; David A Tuveson; Jan Grimm; Laura Lintault; Jamie Newman; Elizabeth E Reczek; Ralph Weissleder; Tyler Jacks
Journal:  Nature       Date:  2007-01-24       Impact factor: 49.962

3.  Essential role for oncogenic Ras in tumour maintenance.

Authors:  L Chin; A Tam; J Pomerantz; M Wong; J Holash; N Bardeesy; Q Shen; R O'Hagan; J Pantginis; H Zhou; J W Horner; C Cordon-Cardo; G D Yancopoulos; R A DePinho
Journal:  Nature       Date:  1999-07-29       Impact factor: 49.962

4.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

Review 5.  The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression.

Authors:  Francois Ghiringhelli; Cédric Ménard; Francois Martin; Laurence Zitvogel
Journal:  Immunol Rev       Date:  2006-12       Impact factor: 12.988

6.  Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

Authors:  Vladimir J N Bykov; Natalia Issaeva; Alexandre Shilov; Monica Hultcrantz; Elena Pugacheva; Peter Chumakov; Jan Bergman; Klas G Wiman; Galina Selivanova
Journal:  Nat Med       Date:  2002-03       Impact factor: 53.440

Review 7.  TP53 and liver carcinogenesis.

Authors:  Frank Staib; S Perwez Hussain; Lorne J Hofseth; Xin W Wang; Curtis C Harris
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

8.  Ras induces vascular smooth muscle cell senescence and inflammation in human atherosclerosis.

Authors:  Tohru Minamino; Toshihiko Yoshida; Kaoru Tateno; Hideyuki Miyauchi; Yonzeng Zou; Haruhiro Toko; Issei Komuro
Journal:  Circulation       Date:  2003-10-13       Impact factor: 29.690

9.  Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice.

Authors:  L D Shultz; P A Schweitzer; S W Christianson; B Gott; I B Schweitzer; B Tennent; S McKenna; L Mobraaten; T V Rajan; D L Greiner
Journal:  J Immunol       Date:  1995-01-01       Impact factor: 5.422

10.  Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.

Authors:  Feng Hong; Richard D Hansen; Jun Yan; Daniel J Allendorf; Jarek T Baran; Gary R Ostroff; Gordon D Ross
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

View more
  1017 in total

1.  Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma.

Authors:  Kenzo Ohara; Takayuki Ohkuri; Takumi Kumai; Toshihiro Nagato; Yui Nozaki; Kei Ishibashi; Akemi Kosaka; Marino Nagata; Shohei Harabuchi; Mizuho Ohara; Kensuke Oikawa; Naoko Aoki; Yasuaki Harabuchi; Esteban Celis; Hiroya Kobayashi
Journal:  Oncoimmunology       Date:  2018-08-01       Impact factor: 8.110

2.  Dysfunction of nucleus accumbens-1 activates cellular senescence and inhibits tumor cell proliferation and oncogenesis.

Authors:  Yi Zhang; Yan Cheng; Xingcong Ren; Tsukasa Hori; Kathryn J Huber-Keener; Li Zhang; Kai Lee Yap; David Liu; Lisa Shantz; Zheng-Hong Qin; Suping Zhang; Jianrong Wang; Hong-Gang Wang; Ie-Ming Shih; Jin-Ming Yang
Journal:  Cancer Res       Date:  2012-06-04       Impact factor: 12.701

Review 3.  Using mice to examine p53 functions in cancer, aging, and longevity.

Authors:  Lawrence A Donehower
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-11-04       Impact factor: 10.005

Review 4.  p53 regulation of metabolic pathways.

Authors:  Eyal Gottlieb; Karen H Vousden
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-02       Impact factor: 10.005

Review 5.  Mouse models of p53 functions.

Authors:  Guillermina Lozano
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

6.  Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells.

Authors:  Anna E Vilgelm; Jeff S Pawlikowski; Yan Liu; Oriana E Hawkins; Tyler A Davis; Jessica Smith; Kevin P Weller; Linda W Horton; Colt M McClain; Gregory D Ayers; David C Turner; David C Essaka; Clinton F Stewart; Jeffrey A Sosman; Mark C Kelley; Jeffrey A Ecsedy; Jeffrey N Johnston; Ann Richmond
Journal:  Cancer Res       Date:  2014-11-14       Impact factor: 12.701

Review 7.  Senescent cells: an emerging target for diseases of ageing.

Authors:  Bennett G Childs; Martina Gluscevic; Darren J Baker; Remi-Martin Laberge; Dan Marquess; Jamie Dananberg; Jan M van Deursen
Journal:  Nat Rev Drug Discov       Date:  2017-07-21       Impact factor: 84.694

Review 8.  Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus.

Authors:  Dirk P Dittmer; Susan E Krown
Journal:  Curr Opin Oncol       Date:  2007-09       Impact factor: 3.645

9.  Oxidative Stress Increases the Number of Stress Granules in Senescent Cells and Triggers a Rapid Decrease in p21waf1/cip1 Translation.

Authors:  Xian Jin Lian; Imed-Eddine Gallouzi
Journal:  J Biol Chem       Date:  2009-01-28       Impact factor: 5.157

10.  Antiproliferative and apoptotic-inducing potential of ellagic acid against 1,2-dimethyl hydrazine-induced colon tumorigenesis in Wistar rats.

Authors:  Syed Umesalma; Ponnuraj Nagendraprabhu; Ganapasam Sudhandiran
Journal:  Mol Cell Biochem       Date:  2013-11-27       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.